PRELIMINARY PROGRAMME
|
|
- Esmond Goodman
- 6 years ago
- Views:
Transcription
1 PRELIMINARY PROGRAMME 26 May 2017 ITALIAN LANGUAGE SYMPOSIUM PHARMACOLOGY IN INTERVENTIONAL CARDIOLOGY DAPT AFTER PCI CONTROVERSY 1 - P2Y12 INHIBITION AFTER PCI IN STABLE PATIENTS Clopidogrel remains the best option in real life Direct-acting P2Y12 inhibitors should be preferred CONTROVERSY WHICH P2Y12 INHIBITOR SHOULD WE USE IN ACS? What guidelines suggest What real world registries show LONG-TERM MANAGEMENT OF PCI PATIENTS CONTROVERSY 1 THERAPY IN HIGH RISK PATIENTS Medical therapy optimization with multiple drugs The newer Polypill is the solution CONTROVERSY 2 ADHERENCE TO DRUGS Compliance to treatment as a major determinant of outcome Strategies to improve patient adherence to treatment LUNCH
2 ANTICOAGULATION IN PCI PATIENTS WITH ATRIAL FIBRILLATION CONTROVERSY 1 THE CHOICE OF NOACS AFTER PCI Phase 3 trials only must guide drug selection Real world data help physicians choice CONTROVERSY 2 NOACS IN PCI AND SURGERY Should NOACs be interrupted in case of PCI? How NOACs should be used in case of surgery? THE FUTURE OF ANTIPLATELETS AND ANTICOAGULANTS AFTER PCI CONTROVERSY 1 THE FUTURE OF P2Y12 INHIBITION Life long dual antiplatelet therapy Only ticagrelor without aspirin CONTROVERSY 2 THE FUTURE OF NOACS Will NOACs and aspirin never be associated? Will NOACs become indicated also in patients with SCA? PARALLEL WORKSHOP ABOUT CLINICAL TRIALS 26 MAY Welcome introduction and course objectives Giuseppe Rosano (UK), Sven Wassmann (Germany) Perspectives of an Editor-In-Chief Stefan Agewall (Norway) SESSION 1. HOW TO DESIGN AND RUN A CLINICAL TRIAL An overview of the different aspects of clinical trials A. Niessner
3 09.50 Traditional versus novel trial designing Giuseppe Rosano (UK) Planning and organising a clinical trial Basil Lewis (Israel) The logistics of running a clinical trial Basil Lewis (Israel) Refreshments and networking SESSION 2. REGULATORY ASPECTS Requirements from regulatory agencies: endpoints, comparators, type of studies Giuseppe Rosano (UK) Post marketing surveillance T. Walther Lunch and networking SESSION 3. TRIAL CATEGORIES Observational trials and registries G. L. Savarese (Italy) Randomised controlled trials A. Niessner Meta-analyses and systematic reviews G. L. Savarese (Italy) SESSION 4. WHAT S NEXT UPCOMING AND ONGOING CLINICAL TRIALS ACS / Antithrombotics Basil Lewis (Israel) / S. Wassmann (Germany) Lipidology H. Drexel (Austria) Diabetes H. Drexel (Austria) Heart Failure M. Lainscack (Slovenia) Refreshments and networking
4 SESSION 5: GOOD CLINICAL PRACTICE GCP for the busy investigator (certificate included) D. Rolfe Close of day 1 27 MAY Welcome and objectives Giuseppe Rosano (UK), Sven Wassmann (Germany) STATISTICAL ISSUES IN CLINICAL TRIALS BASIC NOTIONS Parallel groups (switch after 60 min): Randomised controlled trials and subgroup analyses - A. Niessner Registries and meta-analyses - G.L. Savarese Refreshments and networking HOW TO INTERPRET CLINICAL TRIAL DATA Examples from recent clinical trials S. Wassmann (Germany) + Panelists THINGS TO KNOW FOR JUNIOR INVESTIGATORS Parallel groups: How to write a manuscript - S. Wassmann (Germany) What you need to know as junior investigator - G. Rosano (UK) Closing remarks G. Rosano (UK), S. Wassmann (Germany) Lunch and networking Close of day 2
5 26 May EuroCVP 2017 OPENING CEREMONY END OF DAY 1 27 May 2017 NEW TARGETS IN THE PREVENTION OF CARDIOVASCULAR DISEASE Chairs: Basil Lewis (Israel), Stefan Agewall (Norway) The pharmacological and non-pharmacological approach to cardiovascular prevention Massimo Piepoli (Italy) The management of lipid profile according to the ESC Guidelines Heinz Drexel (Austria) Management of altered glucose metabolism Itamar Raz (Israel) DIABETES MELLITUS: A CARDIOVASCULAR DISEASE Chairs: Stefan Anker (Germany), Massimo Piepoli (Italy) Cardiovascular risk in diabetics Gianluigi Savarese (Sweden) Lenient or intensive control of glycaemia? Itamar Raz (Israel) Effective at last The new glucose-lowering drugs that reduce cardiovascular events Thomas Walther (Ireland)
6 12.30 LUNCHEON SYMPOSIUM PHARMACOLOGY OF ANTI-ISCHAEMIC THERAPY HOW TO TREAT THE DIFFICULT PATIENT? Chairs: Claudio Ceconi (Italy), Juan Carlos Kaski (UK) Elderly patients with heart failure co-morbidities Andrew Coats (UK) Patients with acute coronary syndromes receiving oral anticoagulants Torp Pederson (Denmark) Ischaemic heart failure with renal and/or liver failure Claudio Ceconi (Italy) Joint Session with the HEART FAILURE ASSOCIATION PHARMACOTHERAPY OF HEART FAILURE Chairs: Petar Seferovic (Serbia), Thomas Walther (Ireland) How to implement the pharmacological therapy of patients with HFrEF Stefan Anker (Germny) Optimisation of RAASi How can we manage K+ Lars Lund (Sweden) The treatment of patients with advanced heart failure Marco Metra (Italy) END OF DAY 2
7 28 May 2017 UPDATE ON ORAL ANTICOAGULATION Chairs: Juan Tamargo (Spain), Thomas Schmidt (Denmark) NOACs for patients with venous thromboembolism and atrial fibrillation Alexander Niessner (Austria) How can we individualise NOACs in everyday practice? Giuseppe Rosano (UK) Anticoagulation in the difficult patient: how to choose the right drug Sven Wassmann (Germany) 10:30 OPEN COFFEE BREAK WITH PANEL DISCUSSION NOAC antidotes. How relevant for clinical practice? Panel: Basil Lewis (Israel), Alexander Niessner (Austria), Giuseppe Rosano (UK), Sven Wassmann (Germany) Current status of antidotes and reversal agents for NOAC Juan Tamargo (Spain) MODERN MANAGEMENT OF CHRONIC ISCHAEMIC HEART DISEASE Chairs: Maurizio Volterrani (Italy) Dan Atar (Norway) Targets for the modern pharmacologic treatment of chronic ischaemic heart disease Juan Carlos Kaski (UK) Combination therapy for the optimal management of chronic stable angina Giuseppe Rosano (UK) Heart rate and cardiac metabolism optimisation Maurizio Volterrani (Italy) Closing discussion END OF DAY 3
8 Organisers EUROPEAN SOCIETY OF CARDIOLOGY The European Heart House Les Templiers 2035 route des colles CS BIOT Sophia Antipolis Cedex France MICOM Srl Via B. Verro, Milan Italy Supported by: Società Italiana di Cardiologia (SIC) Societa' Italiana Cardiologia Ospedalita' Accreditata (SICOA) (Requests pending) Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Italian Heart Failure Association (ITAHFA) CME Provider and Secretariat MICOM Srl Via B. Verro, Milan Italy Tel Fax info@eurocvp.com Website: Location: NH Collection Roma Vittorio Veneto Corso D'Italia Rome Italy
ANNUAL REPORT
Identification Working Group on: Cardiovascular Pharmacotherapy Nucleus Composition (Sept 2014-Sept 2016) (Precise name, surname and country) Chairperson:... Vice-chairperson & Secretary... Past Chairperson...
More informationEuroCVP Rome, Italy May, 2017 SCIENTIFIC PROGRAMME
EuroCVP 2017 26-28 May, 2017 SCIENTIFIC PROGRAMME EuroCVP 2017 26-28 May, 2017 WELCOME MESSAGE SCIENTIFIC RATIONALE There is compelling evidence that in patients with cardiovascular disease and in those
More information08:45-09:00 S1: Opening Ceremony Hall A Chairs: Stefan Agewall, Norway; Basil S. Lewis, Israel
Final Programme as at 16 May, 2016 Session times are subject to changes Sunday, 29 May 2016 08:00-17:00 Registration 08:45-09:00 S1: Opening Ceremony Hall A Chairs: Stefan Agewall, Norway; Basil S. Lewis,
More informationDAPT Essential Messages from ESC Guidelines. Committee for Practice Guidelines
2017 Essential Messages from ESC Guidelines Committee for Practice Guidelines DAPT Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Essential Messages 2017 ESC focused update on dual
More informationCARDIOLOGY I BREAKOUT SESSIONS. May Lisbon PORTUGAL Hotel da Estrela. Atrial Fibrillation/ Venous TromboEmbolism
BREAKOUT SESSIONS CARDIOLOGY I Atrial Fibrillation/ Venous TromboEmbolism Advanced Clinical Knowledge for Pharmacists www.hcpa.pt OUR EXPERTS Helen Williams MRPharmS PGDip(Cardiol) Ipresc \ Consultant
More informationCURRENT STRATEGIES TO OPTIMALLY TREAT PATIENTS WITH DIABETES AND CVD
Associazione Chaira Medica This event is compliant with the Eucomed Code of Ethical Business Practice (www.ethicalmedtech.eu) 5 th Post-graduate Updating Course CURRENT STRATEGIES TO OPTIMALLY TREAT PATIENTS
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationAmerican College of Cardiology 66th Annual Scientific Session (ACC.17):
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com American College of Cardiology 66th Annual Scientific
More informationEssential Messages from ESC Guidelines
Essential Messages from ESC Guidelines Committee for Practice Guidelines AMI-STEMI 2017 Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation Essential
More informationNews Release. For UK Media
News Release For UK Media Bayer plc 400 South Oak Way Reading RG2 6AD www.bayer.co.uk Bayer s Xarelto (rivaroxaban) in combination with single antiplatelet therapy receives positive CHMP opinion for treatment
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationSpecial Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원
Special Conditions of NOAC PCI 가톨릭의대 순환기내과 장성원 Issues on Patients with NOAC PCI Peri-procedural management CKD or dialysis Cardioversion Neurological situations Dual Antiplatelet Therapy with Oral Anticoagulants
More informationDisclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationAfter acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationAdditional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationSCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More information8 th Congress of ECCO
European Crohn s and Colitis Organisation Vienna Austria 8 th Congress of ECCO Austria Center Vienna February 14-16, 2013 The major educational event in the field of Inflammatory Bowel Diseases in Europe
More informationAcute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita
More informationMastering the treatment of Depression and Schizophrenia
Florence January 17-18, 2017 Palazzo dei Congressi Piazza Adua, 1 Course Director: Andrea Fagiolini Mastering the treatment of Depression and Schizophrenia Advanced Psychopharmacology Course RATIONALE
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Chairpersons Christian W. Hamm Medical Clinic
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More information2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation Thierry Gillebert European Society of Cardiology, Slides kindly provided
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationHigh-sensitive troponin. Introduction. Platelet aggregation inhibition at admission
Neth Heart J (2017) 25:181 185 DOI 10.1007/s12471-016-0939-y GUIDELINES 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationCardio-Pulmonary Update 2013 August 9-21, Detailed Conference Agenda
Cardio-Pulmonary Update 2013 August 9-21, 2013 Detailed Conference Agenda Please Note: Out of respect for your fellow delegates, please arrive at least 5 minutes prior to each session. The sessions will
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More information24 th Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP)
24 th Scientific Meeting of the International Society of Cardiovascular Pharmacotherapy (ISCP) Lugano Switzerland Thursday, May 9 th and Friday, May 10 th 2019 Organized in collaboration with the Working
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Myocardial infarction: secondary prevention in primary and secondary care for patients following a myocardial infarction 1.1
More informationZürcher Herzkurs, New drugs and interactions. LDL - what else?
Zürcher Herzkurs, 29.09.2017 New drugs and interactions LDL - what else? Heinz Drexel, MD, FESC, FAHA, FRCP (Ed.) VIVIT Institut am Akademischen Lehrkrankenhaus Feldkirch, A Private Universität im Fürstentum
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationPRELIMINARY PROGRAMME. 2nd European-Middle East Forum on Managing cardiovascular risk factors in clinical practice 6 December, Istanbul, Turkey
PRELIMINARY PROGRAMME 2nd European-Middle East Forum on Managing cardiovascular risk factors in clinical practice 6 December, 2013 - Istanbul, Turkey Background and aims of the conference Cardiovascular
More informationFLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS
FLORENCE SPORT MEDICINE LIFESTYLE: FROM ATHLETES TO THE PATIENTS preliminary program Promoted by Organized by Mirone di Eleutère, Discobolo Lancellotti, Museo nazionale romano di Palazzo Massimo - Roma
More informationAdvance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY
Advance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY 08:30 10:00 Saturday 17 October 2015 Zeremoniensaal Prinz Eugen Saal Rittersaal Gartensaal Neurologic emergencies Acute cardiovascular
More informationBayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the
More informationUpdate on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
More informationAnticoagulants and antiplatelet therapy in the older patient: Choosing wisely
Anticoagulants and antiplatelet therapy in the older patient: Choosing wisely Rajiv Gulati, MD PhD Advances in Cardiac Arrhythmias & Great Innovations in Cardiology Torino, October 2015 2015 MFMER 3477310-1
More informationPreliminary Programme
Preliminary Programme The scientific programme comprises various styles of presentations and sessions, each offering a unique opportunity to amass new and important scientific information. Optimal management
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationFLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS
FLORENCE SPORT MEDICINE LIFESTYLE: FROM ATHLETES TO THE PATIENTS preliminary program Promoted by Organized by Mirone di Eleutère, Discobolo Lancellotti, Museo nazionale romano di Palazzo Massimo - Roma
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationBRIEF OPENING OF THE MEETING Paolo Ferrari, Chief Medical Officer, Ente Ospedaliero Cantonale WORLD EPIDEMICS JOIN
Preliminary Programme Lugano Scientific Meeting of the 24th International Society of Cardiovascular Pharmacotherapy (ISCP) Palazzo dei Congressi, Lugano, Switzerland May 9th 10th 2019 Credits Swiss Society
More informationScope of the Problem: DAPT and Triple Therapy after Stenting
Scope of the Problem: DAPT and Triple Therapy after Stenting Kurt Huber, MD, FESC, FACC 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Session, August 30, 2010,
More informationHEART OF THE MATTER: cardiac issues in safe endoscopy & sedation
HEART OF THE MATTER: cardiac issues in safe endoscopy & sedation YUVAL KONSTANTINO M.D. CARDIOLOGY DEPARTMENT, ELECTROPHYSIOLOGY UNIT, SOROKA MEDICAL CENTER, BEN-GURION UNIVERSITY OUTLINE 1 2 3 Anticoagulation
More informationEULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE. Monday 12th Wednesday 14th June 2017 Madrid, Spain
EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE Monday 12th Wednesday 14th June 2017 Madrid, Spain ORGANISATION AND COMMITTEE Scientific organisers Esperanza Naredo Tadej Avcin Jelena Voijinovic Paz Collado
More informationEngagement in language assessment / Regions of Europe
Summary table: Engagement in language / Regions of This table lists the statistically significant differences in the engagement in activities by the respondents from different s of : If the word or appears
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More informationFor more information
For more information www.escardio.org/guidelines ESC Guidelines on the Prevention, Diagnosis and Treatment of Infective Endocarditis (New Version 2009)* The Task Force on the Prevention, Diagnosis and
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology
NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK Advances in Cardiac Arrhythmias and Great Innovations in Cardiology Torino, October 15, 2016 Giuseppe Di Pasquale Direttore Dipartimento Medico
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationV Baltic Heart Failure Meeting and Arrhythmias Baltica October Bellevue Park Hotel Riga, 1 Slokas Street, Riga, Latvia Scientific Programme
October 20 V Baltic Heart Failure Meeting and Arrhythmias Baltica 20 21 October Bellevue Park Hotel Riga, 1 Slokas Street, Riga, Latvia Scientific Programme 09:00 12:00 Registration 12:00 12:20 OPENING
More informationOverview of European Consumption Databases
FEDERAL INSTITUTE FOR RISK ASSESSMENT Overview of European Consumption Databases Katrin Büsch Workshop Food Consumption Data and Dietary Exposure in the European Union, 15-16 May 2008, Berlin Introduction
More informationWESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017
WESTERN EUROPE PREVALENCE AND INCIDENCE OF PERIPHERAL ARTERY DISEASE AND CRITICAL LIMB ISCHEMIA 2017 Mary L. Yost 404-520-6652 , LLC 23 Ridge Rd. Beaufort, SC 20097 Copyright Pending 2017 All rights reserved,
More informationOctober 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany
Programme 4 th CVOT Summit in cooperation with D&CVD EASD Study Group October 25-26, 2018 Infinity Hotel & Conference Resort, Munich, Germany Thursday, October 25, 2018 Room Ammersee I 18:00 18:30 Welcome,
More informationREGISTER TODAY! February 9, Sheraton Mahwah Hotel. Program Directors 2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT:
2 ND ANNUAL COMPREHENSIVE CV DISEASE MANAGEMENT: FROM FUNDAMENTALS TO INNOVATION 2018 February 9, 2018 7 am - 5 pm CME Symposium Sheraton Mahwah Hotel 1 International Blvd. (Rte. 17 North) Mahwah, NJ 07495
More information2015 Preliminary Agenda
2015 Preliminary Agenda Revised 10/08/15 THURSDAY, NOVEMBER 12, 2015 PRE-COURSE WORKSHOP LEARNING OBJECTIVES: At the conclusion of this activity, participants will be better able to: 1. Identify subtle
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationEULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE. Monday 12th Wednesday 14th June 2017 Madrid, Spain
EULAR-PReS PAEDIATRIC MUSCULOSKELETAL COURSE Monday 12th Wednesday 14th June 2017 Madrid, Spain ORGANISATION AND COMMITTEE Scientific organisers Esperanza Naredo Tadej Avcin Jelena Vojinovic Paz Collado
More informationResults from the ENSURE-AF study were presented during the ESC Congress 2016 Hot Line session and the full results are published in The Lancet
Press Release ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo s Once-Daily LIXIANA in Patients with Atrial Fibrillation Undergoing Cardioversion ENSURE-AF is the largest clinical
More informationApril 24, Seoul, South Korea
Clinical Update of Resolute Integrity with DAPT Pooled RESOLUTE Clinical Program Josiah N. Wilcox, Ph.D. Chief Scientific Officer, Coronary and RDN Medtronic CardioVascular TCT-AP TCT AP April 24, 2013
More informationPRELIMINARY PROGRAMME H&N Preceptorship: focus on comprehensive management Nice, France
PRELIMINARY PROGRAMME H&N Preceptorship: focus on comprehensive management Live educational course dates The live educational course H&N Preceptorship: Focus on comprehensive management" will be held on
More informationCardiac CT Course Part A First step towards level 2 SCCT registration
29 September 2 October 2016 Philips Customer Education Center Business Central Towers, Dubai Internet City, Sheikh Zayed Road, Dubai, UAE The use of Multi-Detector CT (MDCT) in the diagnosis of various
More informationBayer AG Investor Relations Leverkusen Germany Investor News. Not intended for U.S. and UK Media
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Initiates Xarelto (Rivaroxaban) Study in Patients with Non- Valvular Atrial
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationDisclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC
Disclosures Updates in Acute Coronary Syndromes No Conflicts of Interest Krishan Soni, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Krishan.soni@ucsf.edu Updates in Acute Coronary
More informationAntiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology
Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationESSENTIAL MESSAGES FROM ESC GUIDELINES
ESSENTIAL MESSAGES FROM ESC GUIDELINES Committee for Practice Guidelines To improve the quality of clinical practice and patient care in Europe HCM GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF HYPERTROPHIC
More informationEDUCATIONAL COURSE. MUSCULOSKELETAL ULTRASOUND in RHEUMATOLOGY BASIC COURSE. Course Coordinator Annamaria Iagnocco
EDUCATIONAL COURSE 2019 MUSCULOSKELETAL ULTRASOUND in RHEUMATOLOGY BASIC COURSE Rome, March 21-23, 2019 Course Coordinator Annamaria Iagnocco COURSE PRESENTATION Musculoskeletal ultrasound in rheumatology
More informationLandmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo
Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationCase Challenges in ACS The Very Elderly in the Cath Lab
Case Challenges in ACS The Very Elderly in the Cath Lab Sameh Salama, MD, FSCAI Professor of Cardiology, Cairo University 86 yrs old male IDDM (controlled on insulin and oral hypoglycemics) Hypertensive
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
More informationAntithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?
Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationBiot Technologies for life. Advanced International Inergetix Seminar: Energy and Informational Medicine on Quantum Base
Biot Technologies for life is pleased to invite you to the new Advanced International Inergetix Seminar: Energy and Informational Medicine on Quantum Base Practical methods for use of the Inergetix CoRe
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationDual Antiplatelet Therapy: Time for a Paradigm Shift?
Dual Antiplatelet Therapy: Time for a Paradigm Shift? 5 years after PLATO Experience from the Daily Clinical Practice Hans Rickli Goals with antithrombotic treatment Acute coronary syndrome Risk reduction
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More informationLIQUID BIOPSY: TRACKING CANCER
A.R.Ger.On ONLUS SYMPOSIUM LIQUID BIOPSY: TRACKING CANCER 29-30 April 2016 prog ram Pierre-Auguste Renoir Chemin montant dans les hautes herbes SYMPOSIUM LIQUID BIOPSY: TRACKING CANCER President Paola
More informationUS FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation
Press Release For non-us Healthcare Media Boehringer Ingelheim GmbH Corporate Communications US FDA Approves Pradaxa (dabigatran etexilate) a breakthrough treatment for stroke risk reduction in non-valvular
More informationNew LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017
New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017 A sub-analysis of the ENGAGE AF-TIMI 48 trial found that edoxaban had
More informationBOLZANO March 21-23, 2019
BOLZANO March 21-23, 2019 Parkhotel Laurin Under the auspices of OrganizATION AND COMMITTE Scientific DIRECTOR Prof. Christian Dejaco Rheumatology Unit Azienda Sanitaria Alto Adige Hospital Brunico-Bruneck
More informationPCHF. A novel course in heart failure management POSTGRADUATE COURSE IN HEART FAILURE
PCHF POSTGRADUATE COURSE IN HEART FAILURE A novel course in heart failure management Certified by the European Society of Cardiology (ESC) and the University of Zurich. Based on the new curriculum of the
More informationWHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej
More informationEUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium
EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV GUY DE BACKER Ghent University,Belgium ESC Congress 2012, aug.25-29th, Munich, Germany ESC Congress 2012, aug.25-29th, Munich,
More informationFLORENCE SPORT MEDICINE FLORENCE LIFESTYLE: FROM ATHLETES TO THE PATIENTS
FLORENCE SPORT MEDICINE LIFESTYLE: FROM ATHLETES TO THE PATIENTS Promoted by Organized by Mirone di Eleutère, Discobolo Lancellotti, Museo nazionale romano di Palazzo Massimo - Roma FLORENCE CONVITTO DELLA
More information1 st EULAR-PreS PAED MSUS Course Intermediate
1 st EULAR-PreS PAED MSUS Course Intermediate Madrid, Spain Monday, 10 th June Wednesday, 12 th June 2019 The courses are a combination of lectures and hands-on scanning of models (Basic course) or patients
More informationTriple Therapy: A review of the evidence in acute coronary syndrome. Stephanie Kling, PharmD, BCPS Sanford Health
Triple Therapy: A review of the evidence in acute coronary syndrome Stephanie Kling, PharmD, BCPS Sanford Health Objectives 1. Describe how the presented topic impacts patient outcomes. 2. Review evidence
More information